Vibostolimab (MK-7684) is a humanized immunoglobulin G1 mAb that binds to TIGIT and blocks its interaction with its ligands CD112 and CD155, thereby activating T cells to help kill tumor cells. The gene discussed is PVR; the disease is neoplasm.